Beyond glucose: Cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates

European Heart Journal, Supplement

Volumn 14, Issue SUPPL. B, 2012, Pages

  Shannon, Richard P ^a   Angeli, Franca S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain natriuretic peptide; Cardioprotective effects; Dipeptidyl peptidase 4; Glucagon like peptide 1; Incretins; Stromal cell derived factor 1 ; Type 2 diabetes mellitus

Indexed keywords

ADENYLATE CYCLASE; ALBIGLUTIDE; BRAIN NATRIURETIC PEPTIDE; CD40 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; INCRETIN; INSULIN; LIRAGLUTIDE; MESSENGER RNA; NORADRENALIN; PLACEBO; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOMYOPATHY; CELL INTERACTION; CELL PROLIFERATION; DIABETIC PATIENT; ENDOTHELIAL PROGENITOR CELL; ENZYME SUBSTRATE; FEASIBILITY STUDY; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; NONHUMAN; NORADRENALIN BLOOD LEVEL; PILOT STUDY; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; STUNNED HEART MUSCLE; ZUCKER RAT;

EID: 84869174894     PISSN: 1520765X     EISSN: 15542815     Source Type: Journal    
DOI: 10.1093/eurheartj/sus001     Document Type: Article

References (66)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
2. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731. doi:10.1136/bmj.b4731.
3. Code of Federal Regulations Title 21, Volume 5 [21CFR310.517]. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310. 517. Accessed 24 March 2012.
4. Food and Drug Administration press release. FDA Significantly Restricts Access to the Diabetes Drug Avandia. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2010/ucm226975.htm. Accessed 24 March 2012.
5. Addison D, Aguilar D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep 2011; 13:115-122.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705. (Pubitemid 46048557)
7. Byetta [prescribing information]. San Diego, CA: Amylin Pharmaceuticals; 2011.
8. Victoza [prescribing information]. Princeton, NJ: Novo Nordisk, Inc.; 2012.
9. Tradjenta [prescribing information]. Ridgefield, CT: Boehringer Ingel-heim Pharmaceuticals, Inc.; July 2011.
10. Onglyza [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; December 2011.
11. Januvia [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; November 2011.
12. Galvus [Summary of Product Characteristics]. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000771/WC500020327.pdf. Accessed 5 January 2012.
13. Takeda Core Products. Nesina. Available at: http://www.takeda. com/about-takeda/product-portfolio/article-73.html. Accessed 15 July 2012.
14. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994;134:2156-2164. (Pubitemid 24142957)
15. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978. (Pubitemid 26192194)
16. Kieffer TJ, Habener JF. The glucagon-like peptides. Endo Rev 1999; 20:876-913. (Pubitemid 30647076)
17. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-224.
18. Ban K, Noyan-Ashraf H, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Car-dioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008; 117:2340-2350. (Pubitemid 351653542)
19. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151. (Pubitemid 40105106)
20. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005;19:9-11. (Pubitemid 40767767)
21. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011;25:13-20.
22. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen Y-T, Elahi D, Shannon RP. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005;312:303-308. (Pubitemid 40096482)
23. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2401-H2408. (Pubitemid 41698549)
24. Noyan-Asharaf MH, Momen MA, Ban K, Sadi A-M, Zhou Y-Q, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58:975-983.
25. Poornima I, Bown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure prone rat. Circ Heart Fail 2008;1:153-160.
26. Timmers L, Henriques JP, de Kleijn DP, DeVries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
27. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-1113. (Pubitemid 43764114)
28. Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjær H, Bøtker HE, Wiggers H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1096-H1102.
29. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965. (Pubitemid 38282847)
30. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection faction and functional status in patients with chronic heart failure. J Cardiac Fail 2006;12:694-699. (Pubitemid 44881367)
31. 2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011;10:6-19.
32. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217-234. (Pubitemid 350176695)
33. Hausenloy DJ, Yellon DM. New directions for protecting against is-chaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460. (Pubitemid 38210151)
34. Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, Shannon RP. Glucagon-like peptide-1 increases myocardial glucose uptake via p38aMAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010;3:512-521.
35. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201.
36. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-835. (Pubitemid 23188160)
37. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24. (Pubitemid 29505281)
38. + progenitor cells. J Immunol 2002;169:7000-7008. (Pubitemid 36899288)
39. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts J-P, De Clercq E, De Meester I, Van Damme J. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1a. FEBS Lett 1998;432:73-76. (Pubitemid 28360743)
40. Brandt I, Lambeir A-M, Ketelslegers J-M, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natri-uretic peptide into its des-SerPro form. Clin Chem 2006;52:82-87. (Pubitemid 43032470)
41. Yin Y, Zhao X, Fang Y, Zhao J, Song M, Huang L. SDF-1a involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice. Cardiovasc Pathol 2010;19:218-227.
42. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967. (Pubitemid 27087709)
43. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1a. Diabetes Care 2010;33:1607-1609.
44. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobwitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetes exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002;106:2281-2786.
45. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial is-chemia/reperfusion in rats. Int J Cardiol. 2012;doi:10.1016./j.ijcard.2011. 12.007.
46. Zaruba M-M, Thiess HD, Vallster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsch E, Huber B, Nathan P, Israel L, Imhof A, Herbach N, Assmann G, Wanke R, Mueller-Hoecker J, Steinbeck G, Franz W-M. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009;4:313-323.
47. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-864. (Pubitemid 39070860)
48. Theiss HD, Brenner C, Engelmann MG, Zaruba M-M, Huber B, Henschel V, Mansmann U, Winterspereger B, Reiser M, Steinbeck G, Franz W-M. Safety and efficacy of SITAgliptin plus GRanulocyte-colony stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis. Int J Cardiol 2010;145:282-284.
49. Boerrigter G, Costelo-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007;292:R897-R901. (Pubitemid 46207745)
50. Kuhn M. Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol 2013;166:522-531.
51. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides BNP and NT-pro-BNP: measurement and relevance in heart failure. Vasc Health Risk Manag 2010;6:411-418.
52. Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami S, Yasuno S, Kinoshita H, Chusho H, Tamura N, Ogawa Y, Nakao K. Over-expression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 2004;110:3306-3312. (Pubitemid 39557492)
53. Gomez N, Touihri K, Matheeussen V, Mendes Da Costa A, Mahmoudabady M, Mathieu M, Baerts L, Peace A, Lybaert P, Scharpé S, De Meester I, Bartunek J, Vanderheyden M, Mc Entee K. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 2012;14:14-21.
54. Yin M, Silljé HHW, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011;10:85-94.
55. Kuhn M, Völker K, Schwarz K, Carbajo-Lozoya J, Flögel U, Jacoby C, Stypmann J, van Eikels M, Gambaryan S, Hartmann M, Werner M, Wieland T, Schrader J, Baba HA. The natriuretic peptide/guanylyl cyclase-A system functions as a stress-responsive regulator of angio-genesis in mice. J Clin Invest 2009;119:2019-2030.
56. Mason RP, Jacob RF, Kubant R, Walter MF, Bellamine A, Jacoby A, Mizuno Y, Malinski T. Effect of enhanced glycemic control with saxa-gliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 2011;18:774-783.
57. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009;120:1266-1286.
58. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyper-glycemia in a Nf-Kb-dependent fashion. J Clin Invest 1998;101:1905-1915. (Pubitemid 28226110)
59. Balletshofer BM, Rittig K, Stock J, Lehn-Stefan A, Overkamp D, Dietz K, Häring HU. Insulin resistant young subjects at risk of accelerated atherosclerosis exhibit a marked reduction in peripheral endo-thelial function early in life but not differences in intima-media thickness. Atherosclerosis 2003;171:303-309. (Pubitemid 37486083)
60. Schächinger V, Britten MB, Dimmeler S, Zeiher AM. NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 2001;22:96-101. (Pubitemid 32622194)
61. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary composition and macrophage infiltration in ather-ectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180-2184.
62. Lindsey JB, House JA, Kennedy KF, Marso SP. Diabetes duration is associated with increased thin-cap fibroatheroma detected by intravascu-lar ultrasound with virtual histology. Circ Cardiovasc Interv 2009;2:543-548.
63. Marso SP, House JA, Klauss V, Lerman A, Margolis P, Leon MB. Diabetes mellitus is associated with plaque classified as thin cap fibroather-oma: an intravascular ultrasound study. Diab Vasc Dis Res 2010;7:14-19.
64. Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 2010;401:7-12.
65. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012;59:265-276.
66. Terasaki M, Nagashima M, Watanabe T, Nohtomi K, Mori Y, Miyaazaki A, Hirano T. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism 2011. doi:10.1016/j.metabol.2011.11.011.